Industry News
Nonsteroidal Immunomodulator VVN461 Meets Endpoints in Post-Cataract Surgery Inflammation Trial

VivaVision Biotech has announced promising phase 2 clinical trial results for VVN461, a nonsteroidal...

read more
Nonsteroidal Immunomodulator VVN461 Meets Endpoints in Post-Cataract Surgery Inflammation Trial
December 10, 2024
OneSight EssilorLuxottica Foundation Partners with WHO on SPECS 2030 Initiative

The OneSight EssilorLuxottica Foundation has entered a strategic partnership with the World Health O...

read more
OneSight EssilorLuxottica Foundation Partners with WHO on SPECS 2030 Initiative
December 09, 2024
Cambium Bio Secures Funding to Advance Dry Eye Disease Treatment

Cambium Bio Limited, a clinical-stage regenerative medicine company, announced that it has successfu...

read more
Cambium Bio Secures Funding to Advance Dry Eye Disease Treatment
December 06, 2024
Galimedix Therapeutics Begins Phase 1 Clinical Trial for Oral GAL-101

Galimedix Therapeutics Inc. has announced the initiation of dosing in a Phase 1 clinical trial for o...

read more
Galimedix Therapeutics Begins Phase 1 Clinical Trial for Oral GAL-101
December 06, 2024
Ocular Therapeutix Achieves Key Milestone in SOL-1 Phase 3 Trial for OTX-TKI

Ocular Therapeutix has announced that over 300 patients have been randomized in the SOL-1 Phase 3 tr...

read more
Ocular Therapeutix Achieves Key Milestone in SOL-1 Phase 3 Trial for OTX-TKI
December 05, 2024
EyePoint Pharmaceuticals Doses First Patient in Second Phase 3 LUCIA Trial of Duravyu for Wet AMD

EyePoint Pharmaceuticals has successfully dosed the first patient in the LUCIA trial, marking the st...

read more
EyePoint Pharmaceuticals Doses First Patient in Second Phase 3 LUCIA Trial of Duravyu for Wet AMD
December 05, 2024
Nerve Regrowth Breakthrough Could Offer Hope for Blindness Treatment

Researchers at the University of Connecticut have uncovered promising findings that may pave the way...

read more
Nerve Regrowth Breakthrough Could Offer Hope for Blindness Treatment
December 05, 2024
Promising Results from PolyActiva's PA5108 Glaucoma Implant Clinical Trial

PolyActiva has announced encouraging results from its Phase 2 clinical trial for the PA5108 glaucoma...

read more
Promising Results from PolyActiva's PA5108 Glaucoma Implant Clinical Trial
December 04, 2024
ARPA-H Awards $125 Million for Eye Transplantation Research

The Advanced Research Projects Agency for Health (ARPA-H) has announced funding of up to $125 millio...

read more
ARPA-H Awards $125 Million for Eye Transplantation Research
December 04, 2024
Nicox Completes Patient Enrollment for Denali Phase 3 Trial of NCX 470 in China

Nicox has announced the completion of patient enrollment in China for the Denali Phase 3 trial, whic...

read more
Nicox Completes Patient Enrollment for Denali Phase 3 Trial of NCX 470 in China
December 03, 2024
More